BioAge Labs Q2 net loss $26.1M; dosed first participant in Phase 2 BGE-102 trial

BioAge Labs, Inc.

Net loss $26.1M ($0.58/share) vs $21.6M ($0.60/share) in Q2 2025; R&D spend up $4.6M to $24.4M.
First participant dosed in QUELL-CV Phase 2 trial of BGE-102 (NLRP3 inhibitor); topline data expected H2 2026.
Cash, cash equivalents, and marketable securities $381.3M as of June 30, 2026; sufficient through 2029.
QUELL-DME Phase 1b/2a trial in diabetic macular edema planned to start mid-2026, data mid-2027.
Collaboration revenue flat at $2.4M; APJ agonist IND planned by year-end 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.